Antidepressant-like effect of low dose of scopolamine in the H/Rouen genetic mouse model of depression.
NBQX
Scopolamine
depression
male and female
mouse model
tail suspension test
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
03
12
2020
received:
29
05
2020
accepted:
09
12
2020
pubmed:
15
12
2020
medline:
21
12
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Rodent models of depression are useful for the investigation of cellular and neuronal mechanisms of antidepressant drugs and for the discovery of potential new targets. In this study, we examined the antidepressant-like effect of scopolamine, a non-selective muscarinic antagonist, in a genetic mouse model of depression obtained through a selective breeding strategy and called H/Rouen. In this model, we observed that scopolamine was active both in males and females at a lower dose (0.03 mg/kg) in the tail suspension test, 30 min following its administration, than observed in CD-1 mice. In addition, we showed this antidepressant-like effect was partly inhibited by an injection of 10 mg/kg of the AMPA receptor antagonist NBQX in both males and females, suggesting the antidepressant-like effect of scopolamine was mainly driven by AMPA receptors in the H/Rouen mouse line. Altogether, our results showed the high sensitivity of the H/Rouen mouse model of depression to study the antidepressant-like effects of pharmacological compounds.
Substances chimiques
Antidepressive Agents
0
Scopolamine
DL48G20X8X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-649Subventions
Organisme : Fondation de France
ID : 00081240
Organisme : Institut National pour la Santé et la Recherche Médicale (Inserm)
Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
Slattery D.A., Cryan J.F. The ups and downs of modelling mood disorders in rodents. ILAR J. (2014) 55 297-309.
Malhi G.S., Mann J.J. Depression. Lancet (2018) 392 2299-2312.
O'Leary O.F., Dinan T.G., Cryan J.F. Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur. J. Pharmacol. (2015) 753 32-50.
Duman R.S. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research. (2018) 7 659.
Witkin J.M., Martin A.E., Golani L.K., Xu N.Z., Smith J.L. Rapid-acting antidepressants. Adv. Pharmacol. (2019) 86 47-96.
Podkowa K., Podkowa A., Salat K., Lenda T., Pilc A., Palucha-Poniewiera A. Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology (2016) 111 169-179.
Witkin J.M., Overshiner C., Li X. et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J. Pharmacol. Exp. Ther. (2014) 351 448-456.
Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. (2005) 4 775-790.
Cryan J.F., Mombereau C., Vassout A..The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. (2005) 29 571-625.
Voleti B., Navarria A., Liu R.J. et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry. (2013) 74 742-749.
El Yacoubi M., Bouali S., Popa D. et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc. Natl. Acad. Sci. U. S. A. (2003) 100 6227-6232.
El Yacoubi M., Vaugeois J.M. Genetic rodent models of depression. Curr. Opin. Pharmacol. (2007) 7 3-7.
El Yacoubi M., Rappeneau V., Champion E., Malleret G., Vaugeois J.M. The H/Rouen mouse model displays depression-like and anxiety-like behaviors. Behav. Brain Res. (2013) 256 43-50.
Palucha-Poniewiera A., Podkowa K., Lenda T., Pilc A. The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. Prog. Neuropsychopharmacol. Biol. Psychiatry. (2017) 79 155-161.
Martin A.E., Schober D.A., Nikolayev A. et al. Further evaluation of mechanisms associated with the antidepressantlike signature of scopolamine in mice. CNS Neurol. Disord. Drug Targets. (2017) 16 492-500.
Li Y., Zhu Z.R., Ou B.C. et al. Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test. Behav. Brain Res. (2015) 279 100-105.
Addy N.A., Nunes E.J., Wickham R.J. Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test. Behav. Brain Res. (2015).
Yu H., Lv D., Shen M. et al. BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1. Psychiatry Res. (2019) 271 328-334.
Yu H., Li M., Shen X. et al. The requirement of L-type voltage-dependent calcium channel (L-VDCC) in the rapid-acting antidepressant-like effects of scopolamine in mice. Int. J. Neuropsychopharmacol. (2018) 21 175-186.
Andrade A., Brennecke A., Mallat S. et al. Genetic associations between voltage-gated calcium channels and psychiatric disorders. Int. J. Mol. Sci. (2019) 20(14) 3537.